Cargando…
Maximum Somatic Allele Frequency in Combination With Blood-Based Tumor Mutational Burden to Predict the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer: A Pooled Analysis of the Randomized POPLAR and OAK Studies
Background: Blood-based tumor mutational burden (bTMB) was recently found to be suboptimal in predicting overall survival (OS) benefits of atezolizumab over docetaxel among patients with advanced non-small cell lung cancer (NSCLC). The maximum somatic allele frequency (MSAF) is an indicator of the p...
Autores principales: | Chen, Yu-tong, Seeruttun, Sharvesh Raj, Wu, Xiang-yuan, Wang, Zi-xian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6929100/ https://www.ncbi.nlm.nih.gov/pubmed/31921683 http://dx.doi.org/10.3389/fonc.2019.01432 |
Ejemplares similares
-
Equibalancing immune‐related adverse events and anticancer activity of immune checkpoint inhibitors
por: Seeruttun, Sharvesh Raj
Publicado: (2019) -
Re-engineering anti-CTLA-4 antibodies for enhancing cancer immunotherapy efficacy and safety
por: Seeruttun, Sharvesh Raj
Publicado: (2019) -
A New Strategy Using ALDH(high)-CD8+T Cells to Inhibit Tumorigenesis
por: Luo, Huiyan, et al.
Publicado: (2014) -
Maximum Somatic Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden Predicts the Efficacy of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer
por: Dong, Yiting, et al.
Publicado: (2022) -
Prevalence of hypertension and prehypertension in Nepal: a systematic review and meta-analysis
por: Huang, Yun, et al.
Publicado: (2019)